Javascript must be enabled to continue!
Assessment of Knowledge and Perception of Sodium-Glucose Co-transporter 2 (SGLT-2) Inhibitors Prescription among Physicians in Saudi Arabia
View through CrossRef
Background:
Sodium-glucose cotransporter 2 inhibitors are a new class of medications
that have been proven to improve both glycemic control and cardio-renal outcomes. The
knowledge, attitude, and perception toward their prescriptions in Jazan, Saudi Arabia, are still unknown.
Objective:
The study aimed to measure the level of knowledge and attitude toward sodium-glucose
cotransporter 2 inhibitors prescription among physicians in the Jazan region, Saudi Arabia.
Methods:
Data analysis was performed using Statistical Package for the Social Sciences, SPSS 23rd
version. Frequency and percentages were used to display categorical variables. Minimum, maximum,
mean, and standard deviation were used to test numerical variables. Independent t-test and
ANOVA test were both utilized to test the factors associated with knowledge and attitude toward
the use of SGLT-2 inhibitors.
Results:
A total of 65 participants were included in the study. 26.2% had a low knowledge level,
30.8% had a moderate knowledge level, and 43.1% had a high knowledge level of sodium-glucose
cotransporter 2 inhibitors. 9.2% had a low attitude level, 43.1% had a moderate attitude level, and
47.7% had a high attitude level toward sodium-glucose cotransporter 2 inhibitors. Age, professional
status, years of experience, and specialty were significantly associated with attitude but not with
the knowledge of sodium-glucose cotransporter 2 inhibitors prescription.
Conclusion:
While the study cohort scored high in the knowledge and attitude domains of the survey,
a large proportion failed to answer very essential questions in type 2 diabetes management.
An educational awareness program needs to be carried out to strengthen the physicians’ knowledge
of SGLT2 inhibitors prescription.
Bentham Science Publishers Ltd.
Title: Assessment of Knowledge and Perception of Sodium-Glucose Co-transporter 2 (SGLT-2) Inhibitors Prescription among Physicians in Saudi Arabia
Description:
Background:
Sodium-glucose cotransporter 2 inhibitors are a new class of medications
that have been proven to improve both glycemic control and cardio-renal outcomes.
The
knowledge, attitude, and perception toward their prescriptions in Jazan, Saudi Arabia, are still unknown.
Objective:
The study aimed to measure the level of knowledge and attitude toward sodium-glucose
cotransporter 2 inhibitors prescription among physicians in the Jazan region, Saudi Arabia.
Methods:
Data analysis was performed using Statistical Package for the Social Sciences, SPSS 23rd
version.
Frequency and percentages were used to display categorical variables.
Minimum, maximum,
mean, and standard deviation were used to test numerical variables.
Independent t-test and
ANOVA test were both utilized to test the factors associated with knowledge and attitude toward
the use of SGLT-2 inhibitors.
Results:
A total of 65 participants were included in the study.
26.
2% had a low knowledge level,
30.
8% had a moderate knowledge level, and 43.
1% had a high knowledge level of sodium-glucose
cotransporter 2 inhibitors.
9.
2% had a low attitude level, 43.
1% had a moderate attitude level, and
47.
7% had a high attitude level toward sodium-glucose cotransporter 2 inhibitors.
Age, professional
status, years of experience, and specialty were significantly associated with attitude but not with
the knowledge of sodium-glucose cotransporter 2 inhibitors prescription.
Conclusion:
While the study cohort scored high in the knowledge and attitude domains of the survey,
a large proportion failed to answer very essential questions in type 2 diabetes management.
An educational awareness program needs to be carried out to strengthen the physicians’ knowledge
of SGLT2 inhibitors prescription.
Related Results
Therapeutic potential of SGLT-2 inhibitors and DDP4 inhibitors in elderly patients with type 2 diabetes mellitus and benign prostatic hyperplasia
Therapeutic potential of SGLT-2 inhibitors and DDP4 inhibitors in elderly patients with type 2 diabetes mellitus and benign prostatic hyperplasia
Background. Benign prostatic hyperplasia (BPH) has recently been linked to diabetes mellitus and insulin resistance. This study aims to explore whether the use of either sodium-glu...
Impact of Common Anticoagulants on Complete Blood Count Parameters Among Humans
Impact of Common Anticoagulants on Complete Blood Count Parameters Among Humans
Abstract
Introduction
Among the most frequently used anticoagulants in hematological testing are tetra-acetic acid (EDTA), sodium citrate, and sodium heparin. However, there is a n...
Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors
Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors
Aims:
Empagliflozin is a selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor in clinical development for the treatment of type 2 diabetes mellitus. This...
Evaluation Of The Effect Of SGLT-2 Inhibitors On Atrial Fibrillation Recurrence In Diabetic Patients
Evaluation Of The Effect Of SGLT-2 Inhibitors On Atrial Fibrillation Recurrence In Diabetic Patients
jabbrv-ltwa-all.ldf
jabbrv-ltwa-en.ldf
Background and Aim
: The relationship between SGLT-2 (sodium
glucose cotransporter-2) inhibitors and atri...
The effects of SGLT-2 inhibitors on cognitive function in patients with type 2 diabetes in AIMS Hospital MZD AJK
The effects of SGLT-2 inhibitors on cognitive function in patients with type 2 diabetes in AIMS Hospital MZD AJK
Background: Type 2 diabetes mellitus (T2DM) has been associated with an increased risk of cognitive impairment due to chronic hyperglycemia, insulin resistance, and vascular dysfun...
Efficacy of Initiating Sodium Glucose Co Transporter 2 Inhibitor (SGLT2I) for Treatment of Type II Diabetes Mellitus
Efficacy of Initiating Sodium Glucose Co Transporter 2 Inhibitor (SGLT2I) for Treatment of Type II Diabetes Mellitus
Sodium glucose co-transporter 2 (SGLT 2) inhibitors are hypoglycemic agents that have action on kidneys. They cause increased excretion of glucose via kidneys by reducing its absor...
Abstract 4140617: SGLT-2 Inhibitors and Atrial Fibrillation Incidence Following Heart Failure Hospitalization in a Diabetic Population
Abstract 4140617: SGLT-2 Inhibitors and Atrial Fibrillation Incidence Following Heart Failure Hospitalization in a Diabetic Population
Introduction:
The development of atrial fibrillation (AF) in patients with heart failure (HF) is associated with increased morbidity and mortality. Initially developed ...
801-P: SGLT2 Inhibitor, Luseogliflozin, Prevent Sarcopenia by Improving Extracellular Lipidome
801-P: SGLT2 Inhibitor, Luseogliflozin, Prevent Sarcopenia by Improving Extracellular Lipidome
Aims: It has been reported that there is a close relationship between sarcopenia obesity and metabolic disorder such as lipid metabolism. Here we investigated the effect on lipid m...

